JJC8-089 explained

Class:Dopamine reuptake inhibitor
Pubchem:90389439
Chemspiderid:76721417
Chembl:3916231
Iupac Name:1-[4-[2-[bis(4-fluorophenyl)methylsulfanyl]ethyl]piperazin-1-yl]propan-2-ol
C:22
H:28
F:2
N:2
O:1
S:1
Smiles:CC(CN1CCN(CC1)CCSC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)O
Stdinchi:1S/C22H28F2N2OS/c1-17(27)16-26-12-10-25(11-13-26)14-15-28-22(18-2-6-20(23)7-3-18)19-4-8-21(24)9-5-19/h2-9,17,22,27H,10-16H2,1H3
Stdinchikey:MQDDJWTVOBHYHX-UHFFFAOYSA-N

JJC8-089 is a dopamine reuptake inhibitor (DRI) that was derived from modafinil and is related to JJC8-016, JJC8-088, and JJC8-091.[1] [2] Its affinity (Ki) for the dopamine transporter (DAT) is 37.8nM, for the norepinephrine transporter (NET) is 11,820nM (313-fold lower than for the DAT), for the serotonin transporter (SERT) is 6,800nM (180-fold lower than for the DAT), and for the sigma σ1 receptor is 2.24nM (17-fold higher than for the DAT).[3] It also has significant affinity for several dopamine receptors. JJC8-089 has substantially higher affinity for the DAT than modafinil. The drug shows pro-motivational effects in animals.[4] [5] It was first described in the scientific literature by 2016.[6] [7]

See also

Notes and References

  1. Book: Aggarwal S, Mortensen OV . Discovery and Development of Monoamine Transporter Ligands . Drug Development in Psychiatry . Adv Neurobiol . Advances in Neurobiology . 30 . 101–129 . 2023 . 36928847 . 10074400 . 10.1007/978-3-031-21054-9_4 . 978-3-031-21053-2 .
  2. Newman AH, Ku T, Jordan CJ, Bonifazi A, Xi ZX . New Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders . Annu Rev Pharmacol Toxicol . 61 . 609–628 . January 2021 . 33411583 . 9341034 . 10.1146/annurev-pharmtox-030220-124205 .
  3. Giancola JB, Bonifazi A, Cao J, Ku T, Haraczy AJ, Lam J, Rais R, Coggiano MA, Tanda G, Newman AH . Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability . Eur J Med Chem . 208 . 112674 . December 2020 . 32947229 . 7680422 . 10.1016/j.ejmech.2020.112674 .
  4. Salamone JD, Correa M . The Neurobiology of Activational Aspects of Motivation: Exertion of Effort, Effort-Based Decision Making, and the Role of Dopamine . Annu Rev Psychol . 75 . 1–32 . January 2024 . 37788571 . 10.1146/annurev-psych-020223-012208 . 10234/207207 . free .
  5. Ecevitoglu A, Meka N, Rotolo RA, Edelstein GA, Srinath S, Beard KR, Carratala-Ros C, Presby RE, Cao J, Okorom A, Newman AH, Correa M, Salamone JD . Potential therapeutics for effort-related motivational dysfunction: assessing novel atypical dopamine transport inhibitors . Neuropsychopharmacology . 49 . 8 . 1309–1317 . July 2024 . 38429498 . 10.1038/s41386-024-01826-1 . 11224370 . July 1, 2025 .
  6. Cao J, Slack RD, Bakare OM, Burzynski C, Rais R, Slusher BS, Kopajtic T, Bonifazi A, Ellenberger MP, Yano H, He Y, Bi GH, Xi ZX, Loland CJ, Newman AH . Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors . J Med Chem . 59 . 23 . 10676–10691 . December 2016 . 27933960 . 5161041 . 10.1021/acs.jmedchem.6b01373 .
  7. Tunstall BJ, Ho CP, Cao J, Vendruscolo JC, Schmeichel BE, Slack RD, Tanda G, Gadiano AJ, Rais R, Slusher BS, Koob GF, Newman AH, Vendruscolo LF . Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats . Neuropharmacology . 131 . 96–103 . March 2018 . 29217282 . 5820113 . 10.1016/j.neuropharm.2017.12.006 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "JJC8-089".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.